Effect of zinc deficiency on chronic kidney disease progression and effect modification by hypoalbuminemia.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 02 02 2021
accepted: 27 04 2021
entrez: 11 5 2021
pubmed: 12 5 2021
medline: 26 10 2021
Statut: epublish

Résumé

Serum zinc (Zn) levels tend to be low in chronic kidney disease (CKD) patients. This cohort study was conducted to investigate the relationship between zinc deficiency and CKD progression. Patients were classified into two groups based on Zn levels < 60 μg/dl (low-Zn group, n = 160) and ≥ 60 μg/dl (high-Zn group, n = 152). The primary outcome was defined as end-stage kidney disease (ESKD) or death and was examined over a 1-year observation period. Overall, the mean Zn level was 59.6 μg/dl and the median eGFR was 20.3 ml/min/1.73 m2. The incidence of the primary outcome was higher in the low-Zn group (p<0.001). Various Cox proportional hazards models adjusted for baseline characteristics showed higher risks of the primary outcome in the low-Zn group than in the high-Zn group. Competing risks analysis showed that low Zn levels were associated with ESKD but not with death. Moreover, in propensity score-matched analysis, the low-Zn group showed a higher risk of the primary outcome [adjusted hazard ratio 1.81 (95% confidence interval 1.02, 3.24)]. Furthermore, an interaction was observed between Zn and serum albumin levels (interaction p = 0.026). The results of this study indicate that zinc deficiency is a risk factor for CKD progression.

Identifiants

pubmed: 33974681
doi: 10.1371/journal.pone.0251554
pii: PONE-D-21-03589
pmc: PMC8112700
doi:

Substances chimiques

Zinc J41CSQ7QDS

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0251554

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ther Apher Dial. 2009 Jun;13(3):213-9
pubmed: 19527468
Nephrourol Mon. 2015 Jun 30;7(4):e28576
pubmed: 26539418
Kidney Int. 2020 Apr;97(4):753-764
pubmed: 32059999
Am J Physiol Renal Physiol. 2005 Jun;288(6):F1144-52
pubmed: 15687247
Int J Environ Res Public Health. 2018 May 24;15(6):
pubmed: 29795052
Hepatol Res. 2007 Jun;37(6):405-9
pubmed: 17539814
Blood. 2006 Jan 15;107(2):520-7
pubmed: 16174764
Am J Clin Nutr. 2011 Aug;94(2):679S-84S
pubmed: 21715515
J Biol Chem. 2000 Nov 17;275(46):35786-91
pubmed: 10954720
Clin Exp Nephrol. 2017 Jun;21(3):446-456
pubmed: 27412450
Mol Med Rep. 2016 Dec;14(6):5245-5252
pubmed: 27779665
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13567-72
pubmed: 11087827
Am J Clin Nutr. 2001 Jul;74(1):116-24
pubmed: 11451726
Am J Physiol Cell Physiol. 2017 Jan 1;312(1):C47-C55
pubmed: 27806940
J Biol Inorg Chem. 2011 Oct;16(7):1123-34
pubmed: 21660546
J Clin Med Res. 2018 May;10(5):437-444
pubmed: 29581807
Biochim Biophys Acta. 2013 Dec;1830(12):5456-64
pubmed: 23726993
Rev Diabet Stud. 2008 Summer;5(2):102-9
pubmed: 18795212
Cell Mol Life Sci. 2014 Sep;71(17):3281-95
pubmed: 24710731
Curr Med Chem. 2010;17(34):4256-69
pubmed: 20939814
Nephrol Dial Transplant. 2020 Jul 1;35(7):1163-1170
pubmed: 31006015
Acta Biochim Biophys Sin (Shanghai). 2010 Mar 15;42(3):183-94
pubmed: 20213043
J Trace Elem Med Biol. 2006;20(1):3-18
pubmed: 16632171
Free Radic Biol Med. 2004 Oct 15;37(8):1182-90
pubmed: 15451058
J Nutr. 2000 May;130(5S Suppl):1437S-46S
pubmed: 10801957
Kidney Int Suppl. 1989 Nov;27:S269-73
pubmed: 2636669
Endocrine. 2014 Mar;45(2):178-89
pubmed: 23979673
Biochem Biophys Res Commun. 2020 Jan 22;521(4):1049-1054
pubmed: 31732151
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1546-56
pubmed: 27340285
J Nutr Biochem. 2010 Mar;21(3):237-46
pubmed: 19369054
N Engl J Med. 2004 Sep 23;351(13):1285-95
pubmed: 15385655
PLoS Med. 2007 Sep;4(9):e270
pubmed: 17803353
Lab Invest. 2016 Jan;96(1):25-36
pubmed: 26552047
BMC Med. 2009 May 19;7:25
pubmed: 19454005

Auteurs

Atsuyuki Tokuyama (A)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Eiichiro Kanda (E)

Medical Science, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Seiji Itano (S)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Megumi Kondo (M)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Yoshihisa Wada (Y)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Hiroyuki Kadoya (H)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Kengo Kidokoro (K)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Hajime Nagasu (H)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Tamaki Sasaki (T)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Naoki Kashihara (N)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH